QLIFE HOLDING AB, Interim Report Q2, April to June 2024

Restructuring the company

Financial summary – second quarter 2024

• Revenue in the period amounted to kSEK 39 (46).
• EBITDA for the period amounted to kSEK –8,002 (-16,287), and net loss kSEK –12,979 (-22,703).
• The total cash flow in the second quarter amounted to kSEK -4,809 (7,894).
• Earnings per share before/after dilution for the quarter amounted to SEK -0.01 (-0.05), calculated on weighted average number of shares in the period.

Significant events – second quarter of 2024

• On 4. April Qlife enters its Danish subsidiary Qlife Aps into reconstruction. Under Danish law the company can during a reconstrution phase resolve on creditor issues, access certain loans and lower its operational cost.
• On 23. April Qlife resolves on whether the company shall enter into liquidation or continue its operations. The company resolves in accordance with the primary proposal from the board of directors that the company’s operations shall be continued.
• On 8. May Qlife enters into an addendum with the holders of the company’s convertible debentures and all outstanding convertible debentures are converted into shares.
• On 3. June Qlife and its Chinese partner Hipro Biotechnology finalize validation of biomarker C-Reactive Protein (CRP) on Egoo Health and starts clinical testing in China. CRP is one of the most used biomarkers for inflammatory diseases and to monitor infection levels in relation to antibiotic treatment and represents a significant potential in the home-hospital segment.
• On 24. June it is announced that Qlife loses arbitration proceedings against Aidian Oy. Qlife is ordered to pay MEUR 0.80 to Aidian plus annual interest of 10.00 per cent, MEUR 0.26 for legal fees, and MEUR 0.07 for the fees and costs to the arbitrator as well as administrative costs related to the arbitration proceedings.

Significant events after the end of the second quarter of 2024

• On 2. July Qlife announces that it has participated a research trial in the USA for people living with PKU (phenylketonuria) and achieved positive data. Qlife was invited to participate a metabolic camp focused on young women at Emory University and run a research trial with the aim of making a comparison study of blood data on Egoo Health compared to data from normal laboratory routines.
• On 17. July updates that the reverse split approved at the 26. June general meeting shall take effect from 31. July. The spilt consist of a merger where thousand (2,000) existing shares shall be merged into one (1) share.
• On 19. July Qlife announces that it will file for bankruptcy for its Danish subsidiary Qlife Aps, which is under restructuring already. The reasons are (i) the outcome of the arbitration proceedings against Aidian Oy, (ii) the decreased market value of Qlife, and (iii) the capital requirements for Qlife Aps. The listed parent company, Qlife, will continue its operations, and will investigate a capital raise to create financial preconditions to submit an offer to acquire the Qlife Aps assets from the estate and to secure sufficient working capital.

The full report is attached and can also be found here: https://qlifeholding.com/en/investors/finansiella-rapporter

Letter from the CEO

Restructuring the company

On the legal and financial side, we faced some significant challenges this quarter, while on the operational side, we have been moving forward according to our plan and strategy.

The expectation was that we would be able to emerge from the reconstruction phase with our Danish operational company. In fact, we had been negotiating a financing instrument with a London-based fund. However, at the end of June, we were informed that we had lost our arbitration case in Finland towards Aidian Oy. Our claims had been dismissed and their claims against us had been adopted, which resulted in a much larger debt situation for the company.

Therefore, on July 19, we had to file for bankruptcy for our Danish subsidiary, as there was no other alternative. Although this is not an ideal situation, it also gave us the opportunity to consider a complete restructuring of the company. Since then, we have been working on cleaning up the company’s balance sheet as well as reacquiring the fundamental intangible and tangible assets from the subsidiary. At the time of the release of this report we are still working on that process, and to secure sufficient working capital for the company to move forward.

Interestingly, our operational focuses have progressed quite nicely during the quarter. In June our Chinese partner, Hipro, initiated the first trial of the biomarker C-Reactive Protein (CRP) on the Egoo Health platform in China. CRP is one of the most commonly used biomarkers for inflammatory diseases and for monitoring infection levels in relation to antibiotic treatment. This represents significant potential in the home-hospital segment, which is our primary focus.

In July, we announced that Qlife had been invited to participate in a metabolic camp at Emory University, USA, focused on young women with Phenylketonuria (PKU). We conducted a research trial with the aim of comparing blood data from the Egoo Health platform to data obtained through standard laboratory routines, and we achieved excellent data. The people there were quite excited about the prospect of having a blood at home-monitoring device that allows them to immediately see how the body reacts to their diets.

Of course, the legal and financial challenges have slowed down our ability to support our operations in China and our efforts in the rare disease category, but nevertheless things have moved forward, and I do not see that we operationally have been very much affected by the constraints.

We continue to focus on providing support, particularly to Hipro in their effort to setup production of Egoo Health at their facilities. Additionally, we are maintaining our efforts on performance data protocols and trial processes to become a first mover in the home-hospital segment with an approved self-testing immuno-diagnostics platform. We also anticipate potentially significant progress in the rare disease field, specifically with PKU. The company was originally built on a promise to alleviate life for the children and teenagers living with this rare disease. And in the long term, the platform may also be able to target other areas of rare diseases.

Our focus is now on solving the legal and capital requirement and get Egoo Health back into action.

Helsingborg 29 August 2024

Thomas Warthoe, CEO

This disclosure contains information that Qlife Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 2024-08-29 08:00 CET.